Last updated on May 2018

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Brief description of study

Primary Objective:

To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity

Secondary Objective:

Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Clinical Study Identifier: NCT03371108

Find a site near you

Start Over

Suncoast Clinical Research, Inc.

New Port Richey, FL United States
  Connect »

Metabolic Research Institute

West Palm Beach, FL United States
  Connect »

Terence T. Hart, MD

Tuscumbia, AL United States
  Connect »

Sestron Clinical Research

Marietta, GA United States
  Connect »

L-MARC Research Center

Louisville, KY United States
  Connect »

Peninsula Research

Ormond Beach, FL United States
  Connect »

Meridien Research

Bradenton, FL United States
  Connect »

Chase Medical Research, LLC

Waterbury, CT United States
  Connect »

Midwest CRC

Crystal Lake, IL United States
  Connect »

Palm Research Center, Inc.

Las Vegas, NV United States
  Connect »

Physicians East, PA

Greenville, NC United States
  Connect »

Lillestol Research LLC

Fargo, ND United States
  Connect »

Aventiv Research, Inc.

Columbus, OH United States
  Connect »

Simon Williamson Clinic

Birmingham, AL United States
  Connect »

Family Practice Specialists

Phoenix, AZ United States
  Connect »

Valley Research

Fresno, CA United States
  Connect »

Genoma Research Group

Miami, FL United States
  Connect »

Oviedo Medical Research

Oviedo, FL United States
  Connect »

iResearch Atlanta

Decatur, GA United States
  Connect »